At the news
? BULLISHIMPACT 7/10 8-K filed Apr 20, 2026 at 07:01 ET
Cabaletta Bio updated its corporate presentation with clinical data showing positive safety and efficacy results from its autoimmune-focused CAR-T therapy rese-cel across multiple trials, including myositis, lupus, and myasthenia gravis, while advancing innovations in preconditioning elimination and automated manufacturing.
- Posted updated corporate presentation with clinical data from RESET trials
- Rese-cel demonstrated favorable safety profile with 95% of patients experiencing no or Grade 1 CRS
- Positive efficacy data in multiple autoimmune conditions including myositis, SLE, and myasthenia gravis
- Advancing innovations in preconditioning elimination and automated manufacturing
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access